Epicrispr, Infinimmune snag combined $165M in VC cash
Epicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.
Epicrispr, Infinimmune snag combined $165M in VC cash Read More »
